Cancer heat therapy is leaving the lab. Magnetic hyperthermia heats tumors from inside using iron-oxide nanoparticles and alternating magnetic fields. In 2025, Nature reported stronger chemoradiation effects in glioblastoma models [1] small signal, big implication. 🧲 Money is moving too: the market hit $40.2M in 2024 and is projected near $611.6M by 2034 [2]. New reviews still flag delivery, selective heating, and thermal control [3]. ⚕️ For leaders, the test is standardizing particles, coils, QA, imaging, and training fast enough. 🤔 What would convince you first: survival data, regulation, or hospital adoption? [1] [nature.com/articles/s41598-0…](nature.com/articles/s41598-0…) [2] [gminsights.com/industry-anal…](gminsights.com/industry-anal…) [3] [mdpi.com/2079-4991/15/19/151…](mdpi.com/2079-4991/15/19/151…) #MagneticHyperthermia #Nanomedicine #CancerTech

Cancer heat therapy is back. Magnetic hyperthermia is leaving the lab. A 2025 first-in-human report in advanced cancer showed disease stabilization with no significant side effects [1]. Nature now frames imaging-guided magnetic nanoparticles as a route to more precise tumor heating [2]. 🎯 The market signal: $163.6M in 2025 to $1.6B by 2034 [3]. That means device jobs, materials IP, and a new nanomedicine race ⚠️ Now comes the hard part: prove survival benefit, improve targeting, and make systems viable beyond elite centers. 🤔 Where is the weakest link: evidence, delivery precision, or cost? [1] [frontiersin.org/articles/10.…](frontiersin.org/articles/10.…) [2] [nature.com/articles/s44222-0…](nature.com/articles/s44222-0…) [3] [gminsights.com/industry-anal…](gminsights.com/industry-anal…) #CancerTech #MagneticHyperthermia #Nanomedicine

They let me map cancertech for a tourney

A new MRM Health R&D partnership in immunotherapy points to broader clinical and investment upside. longevity.technology/news/mr… #longevity #Microbiome #Immunotherapy #CancerTech #BioInnovation #FutureMedicine

🚀 Breaking through brain cancer barriers! $PSTV’s REYOBIQ™ targets tough CNS tumors like glioblastoma & LM with precision radiation. Fresh ‘Buy’ rating from D. Boral Capital, consensus targets ~$8 (1,300% upside from $0.58). Milestones ahead: Trial data & Phase 2 push. Do Your Own Research 👀 #PSTV #CancerTech #Investing

🚨 $HIMS JOINS $GRAL CANCER REVOLUTION: $325M FUNDING BOMB FOR EARLY DETECTION! 🧬💉 Shares up 14% premarket—telehealth meets oncology moonshot! Load up? 🔥 #HIMS #GRAL #CancerTech

I will be speaking on July 17 alongside top researchers at the 2025 Silicon Valley Cancer Technology Conference. I hope you'll join me! #cancertech eventbrite.com/e/2025-silico…

$BIAF – Biotech beast mode! 🧬 Up 52% premarket! 🔹 CyPath® Lung sales up 276% YoY – traction confirmed 💥 🔹 New patents locked in for siRNA cancer therapies 🧠 🔹 Cardinal Health deal = logistics boost 🚚 🔹 Micro-cap rocket: $7M cap, low float = liftoff conditions 🚀 🔹 Technical breakout in play – eyes on volume 📊 $BIAF – diagnostics name heating up! 🔬 #BIAF #Biotech #CancerTech #MicroCap #PremarketRip

I will be speaking on July 17 alongside a panel of experts at the 2025 Silicon Valley Cancer Technology Conference. I hope you'll join me!#cancertech #SiliconValley eventbrite.com/e/2025-silico… cancerstartup.com/

#skanestartups #biotech company Asgard Therapeutics (@AsgardThx) strengthens governance and advisory capacity for AT-108 development. By @arcticstartup arcticstartup.com/asgard-the… #NordicMade #nordicbiotech #cancertech #Lundstartups

The RefleXion X1 with SCINTIX therapy is the only hybrid platform that offers both breakthrough biologic and best-in-class anatomic capabilities to treat solid tumors of any stage. #SCINTIX #RefleXion #CancerTreatment #CancerTech

🔬See how the ML7710 laser is used in real oncology cases: bladder, H&N, glioblastoma. Light is changing cancer care. 🔗 Oncology use cases: modulight.com/applications/o… 🎥 Magic With Light ep. 1: youtu.be/Bz7FHbuSu5w?si=CXNW… #Modulight #ML7710 #Oncology #PhotodynamicTherapy #CancerTech

Avacta’s pre|CISION® platform powers AVA6103, a peptide drug conjugate that sustains exatecan release in tumors for over 60 hours. With a reported 75-fold TI boost, it targets cancer potently while cutting toxicity—a precision oncology leap. #OncologyInvesting #CancerResearchFunding #BiotechInvestors #OncologyInnovation #CancerTech #AVCT

Avacta’s pre|CISION® platform powers AVA6103, a peptide drug conjugate that sustains exatecan release in tumors for over 60 hours. With a reported 75-fold TI boost, it targets cancer potently while cutting toxicity—a precision oncology leap. #OncologyInvesting #CancerResearchFunding #BiotechInvestors #OncologyInnovation #CancerTech #AVCT Avacta’s pre|CISION® Platform : This proprietary technology uses FAP (Fibroblast Activation Protein)-cleavable peptides to activate potent warheads like exatecan specifically in the tumor microenvironment 60 Hours in Tumor Preclinical data from AACR 2025 shows AVA6103’s linker sustains exatecan release for over 60 hours in tumors, enhancing exposure and efficacy compared to free exatecan’s short half-life

The first ever Czech hackathon against cancer attracted over 150 IT students, physicians and other experts for a sleepless weekend in Prague. Congratulations to all the winners and hats down to all the participants. #rakathon was organized under the auspices of @prezidentpavel by @FnMotol @2LFUK @insanebui See rakathon.cz for full results. #cancertech #medtech #healthtech #innovation

🧬 Color Health's AI Copilot - Fast-tracking cancer care with AI, reducing treatment delays. #CancerTech #AICancerCare aihealthtech-insider.beehiiv…

Most patients with stage four cancer are not considered candidates for definitive radiotherapy. The good news? Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer. #RefleXion #CancerTherapy #CancerTreatment #CancerAwareness #CancerTech

An inspiring afternoon with @AmericanCancer! @theNCI co-hosted an event with entrepreneurs and leaders focused on innovation and developing cancer technologies to improve women's health. Great fireside chat with ACS leadership and I even got to moderate a panel. #SBIR #CancerTech

World Theranostics Day commemorates the continuous progress and evolution in nuclear medicine. Over eight decades ago, Dr. Saul Hertz marked a historic moment by administering the inaugural therapeutic dose of radioactive iodine to a patient, reshaping the landscape of cancer treatment. In the spirit of Dr. Hertz, we want to leverage radiopharmaceuticals to change the approach to treating metastatic disease. #RefleXion #scintix #theranostics #CancerTech #MetastaticCancer

@RhyledUp this is just the greatest cancertech of all time